Zim Laboratories Ltd (BSE: 541400) is a Nagpur, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹679 Cr, it ranks #1,790 by market cap among the 6,189 Indian listed companies on FinBizNet, and #53 of 86 in Medicinal Chemicals and Botanical Products. At ₹126.60 (as of 26 Oct 2026), the share price is 20.8% below its 52-week high of ₹159.81 and 113.5% above its 52-week low of ₹59.31. The share price is up 82.7% over one year and up 4.8% over three months.
| Current Price | ₹126.60 |
|---|---|
| Market Cap | ₹679 Cr |
| BSE Code | 541400 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 106.4 |
| Return on Equity | 2.13% |
| Return on Assets | 1.27% |
| 52-Week Range | ₹59.31 – ₹159.81 |
| 1-Year Price Change | +82.7% |
| 3-Month Price Change | +4.8% |
| Beta (1Y) | 0.84 |
| Dividend Yield | 0.00% |
| Headquarters | Nagpur, Maharashtra |
| Website | www.zimlab.in |
| Revenue | ₹94 Cr |
|---|---|
| Net Profit | ₹-4 Cr |
| Net Margin | -4.3% |
| EPS (Basic) | ₹-0.75 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.
1. Pharmaceuticals-This segment manufactures, markets, and sells formulation drugs and pre formulation ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Zim Laboratories Ltd | ₹679 Cr | 106.4 | 2.13% | ₹94 Cr | +82.7% |
Listed by market capitalisation. Ratios are shown for context only.
Zim Laboratories Ltd is trading at ₹126.60, with a market capitalisation of ₹679 Cr.
Zim Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Zim Laboratories Ltd has a P/E of 106.4 and a return on equity of 2.13%.
Zim Laboratories Ltd is listed on the BSE under the scrip code 541400.
Zim Laboratories Ltd's share price is up 82.7% over one year and up 4.8% over three months. Its 52-week range is ₹59.31 to ₹159.81.
In Q1 FY27, Zim Laboratories Ltd reported revenue of ₹94 Cr and net profit of ₹-4 Cr, with basic EPS of ₹-0.75 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.